Chemistry:Uridine triacetate
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Vistogard, Xuriden |
| Other names | vistonuridine |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a616020 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Pyrimidine catabolic pathway |
| Onset of action | Tmax = 2–3 hours |
| Elimination half-life | 2–2.5 hours |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C15H18N2O9 |
| Molar mass | 370.314 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Uridine triacetate (INN),[1] formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine[2] used:
- in the treatment of hereditary orotic aciduria (brand name Xuriden /ˈzʊərədɛn/ ZOOR-ə-den);[3]
- to treat people following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard).[4][5][6][7][8]
Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics. It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015.[9][10][11]
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65". World Health Organization. p. 92. https://www.who.int/medicines/publications/druginformation/innlists/RL65.pdf.
- ↑ "Uridine triacetate — DrugBank Page". 12 March 2017. https://www.drugbank.ca/drugs/DB09144.
- ↑ "Xuriden- uridine triacetate granule". 16 December 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40606ca9-4f14-45b7-8632-fc2d17d11a2e.
- ↑ "Vistogard- uridine triacetate granule". 15 November 2018. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a0ba417-8a4a-4d7f-b85a-1839ee8bd3f1.
- ↑ "BTG Announces FDA Approval of Vistogard (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine". BTG International Ltd.. 11 December 2015. https://www.btgplc.com/media/press-releases/btg-announces-fda-approval-of-vistogard/.
- ↑ "Approved Drugs — Uridine Triacetate". U.S. Food and Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm476930.htm.
- ↑ "Uridine Triacetate". Hospital Pharmacy 51 (6): 484–8. June 2016. doi:10.1310/hpj5106-484. PMID 27354750.
- ↑ "FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs". Clinical Cancer Research 22 (18): 4545–4549. September 2016. doi:10.1158/1078-0432.CCR-16-0638. PMID 27401247.
- ↑ "Xuriden (uridine triacetate) oral granules". 8 October 2015. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208169Orig1s000TOC.cfm.
This article incorporates text from this source, which is in the public domain.
- ↑ "Drug Trials Snapshots: Xuriden". 4 September 2015. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xuriden. This article incorporates text from this source, which is in the public domain.
- ↑ "Previous Cumulative CY CDER BT Approvals" (PDF). https://www.fda.gov/media/95302/download. This article incorporates text from this source, which is in the public domain.
External links
- "Uridine triacetate". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/uridine%20triacetate.
 |  |
